GlassScriptPhysician profile
Ronny D Williams
NPI 1457004533
$4,719.56
in general payments reported to CMS, 2019-2025
33 companies · $1,555 in 2025
The $1,555 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $596 · 2024: $2,568 · 2025: $1,555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,719.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $779.93 | 2023-2025 | Otezla, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $768.07 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $527.07 | 2023-2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $366.48 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $249.75 | 2024 | Voquezna |
| Radius Health, INC. | $238.16 | 2023-2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $200.57 | 2023-2025 | |
| Medline Industries LP | $174.26 | 2025 | |
| Ironwood Pharmaceuticals, INC | $148.76 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $143.80 | 2023-2024 | Inpefa |
| Lilly USA, LLC | $142.11 | 2023-2025 | Jardiance |
| Eisai INC. | $121.88 | 2024 | |
| Biogen, INC. | $109.20 | 2024-2025 | Leqembi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.78 | 2023-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.14 | 2024-2025 | Jardiance |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $76.54 | 2023-2024 | |
| Novo Nordisk INC | $61.14 | 2024-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $56.76 | 2024-2025 | Cologuard Collection Kit |
| Ars Pharmaceuticals Operations, INC. | $44.56 | 2025 | Neffy |
| Pfizer INC. | $39.96 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $39.41 | 2023 | Nuedexta |
| Corcept Therapeutics | $33.11 | 2023-2024 | Korlym |
| Azurity Pharmaceuticals, INC. | $30.33 | 2025 | Alvesco |
| Viatris Specialty LLC | $25.65 | 2025 | Yupelri |
| Abbvie INC. | $22.68 | 2025 | |
| Tms Neurohealth Centers INC. | $21.79 | 2025 | Tms Neurohealth Centers INC. |
| Janssen Pharmaceuticals, INC | $21.43 | 2023 | Xarelto |
| Beta Bionics, INC. | $21.28 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Merck Sharp & Dohme LLC | $18.07 | 2024 | Verquvo |
| Medtronic, INC. | $17.01 | 2024 | Intellis Adaptivestim |
| Takeda Pharmaceuticals U.S.A., INC. | $16.35 | 2024 | Trintellix |
| Esperion Therapeutics, INC. | $15.41 | 2024 | Nexletol |
| Glaxosmithkline, LLC. | $15.12 | 2025 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronny Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.